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The BCL6 gene is a key factor necessary for formation of germinal centers and is implicated 
in pathogenesis of diffuse large B cell lymphoma (DLBCL). In this issue of Cancer Cell, Saito 
and colleagues explore regulation of BCL6 gene expression by CD40-NF-κB signaling pathway 
and show that the IRF4 transcriptional factor, induced by the NF-κB canonical pathway, directly 
downregulates BCL6 expression. The authors further demonstrate that this negative regulatory 
mechanism may be disturbed in DLBCLs harboring BCL6 gene translocations or mutations. 
These finding suggest that IRF4 may function as a key regulator of germinal center reaction and a 
guardian of lymphomagenesis.In response to antigen encounter, 
uncommitted naive B cells are acti-
vated and undergo a complex matura-
tional process yielding phenotypically 
distinct subpopulations, which form 
highly organized germinal centers 
(GC) in lymphoid organs. Within the 
GC, B cells undergo high rate prolif-
eration and affinity maturation, are 
selected by antigen, switch toward 
advanced isotypes, and finally dif-
ferentiate into either memory B cells 
or plasma cells. The maturation 
process leading to the generation of 
GC lymphocytes, and their subse-
quent differentiation to memory and 
plasma cells is characterized by tightly 
regulated suppression or increased 
expression of specific genes, result-
ing in distinctive gene expression 
signatures characterizing individual ontogeny stages of the lympho-
cytes. Currently, known key players 
at the GC stage include BCL6 and 
activation-induced cytidine deami-
nase (AID), the former necessary 
for GC formation while the latter is 
essential for class switch recom-
bination (CSR) and somatic muta-
tions of the immunoglobulin genes. 
Toward the completion of GC reac-
tion and terminal differentiation, 
the expression of these genes is 
downregulated, while genes neces-
sary for plasma cell formation, such 
as IRF4 (also known as MUM-1), 
Prdm1, encoding Blimp-1, and XBP-
1 are expressed. Aberrations in this 
orchestrated process may cause 
deregulated gene expression, lead-
ing to cell transformation and lym-
phomagenesis.Cancer Cell 12, SBCL6 is a proto-oncogene encod-
ing a POZ/Zinc finger sequence-
specific transcriptional repressor, 
which is distinctively expressed in 
GC B cells. In the GC, BCL6 exerts 
antiapoptotic effects and favors 
sustained proliferation of B cells by 
modulating the transcription of genes 
involved in cell cycle regulation, pro-
liferation, activation, CSR, and dif-
ferentiation (Shaffer et al., 2000). The 
expression of BCL6 in the GC lym-
phocytes is tightly regulated at both 
the transcriptional and the protein 
levels. BCL6 gene is negatively self-
regulated by binding of BCL6 to spe-
cific binding sequences located in its 
first exon (Wang et al., 2002). Activa-
tion of STAT5 may either upregulate 
or suppress BCL6 expression, and 
p53 may increase BCL6 expression eptember 2007 ©2007 Elsevier Inc. 189
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The germinal center (GC) reaction starts when naive B cells are activated by antigen in the pres-
ence of costimulatory signals from T cells. These events transform B cells into centroblasts that 
proliferate and undergo somatic mutation of immunoglobulin genes within a histologically de-
fined “dark zone.” Centroblasts then develop into noncycling centrocytes, which are selected 
in the “light zone” based on their ability to bind their cognate antigen with the help of follicular 
dendritic cells (FDC) and T cells. In the light zone of GC, engagement of CD40 on B cells by 
CD40 ligand on the T cells activates NF-κB canonical pathways and induces transcription of 
IRF-4 transcriptional factor. IRF4 can bind to the BCL6 promoter region and downregulates its 
transcription, thus allowing terminal differentiation to post-GC lymphocytes.(Margalit et al., 2006). Stimulation of 
B cell receptor induces MAP-kinase-
mediated phosphorylation of BCL6, 
leading to its degradation by protea-
some pathway (Niu et al., 1998). p300 
mediates BCL6 acetylation, leading 
to inhibition of its transrepressive 
function (Bereshchenko et al., 2002). 
The tight regulation of BCL6 is not 
only imperative for normal lympho-
cyte maturation, but is also implicated 
in lymphomagenesis. The BCL6 gene 
located at 3q37 is involved in recurrent 
chromosomal translocations present 
in approximately 30%–40% of dif-
fuse large B cell lymphomas (DLBCL) 
and 6%–15% of follicular lympho-
mas. The translocations deregulate 
BCL6 expression by placing its intact 
coding sequence under the influ-
ence of a potent heterologous pro-
moter. Such translocations lead to 
deregulated expression of the BCL6 
from the translocated allele (Los-
sos et al., 2003). In addition, the 5′ 
noncoding regulatory region of the 
BCL6 is targeted by deletions and 190 Cancer Cell 12, September 2007 ©20somatic mutation, some of which 
result in deregulated BCL6 expres-
sion. Recently, unequivocal proof for 
BCL6’s role in lymphomagenesis was 
provided by demonstration that con-
stitutive expression of BCL6 in mice 
lymphocytes recapitulates the patho-
genesis of human DLBCL (Cattoretti 
et al., 2005).
In this issue of Cancer Cell, Saito et 
al. achieve an additional milestone in 
elucidation of BCL6 regulation, further 
illuminating the endless complexity of 
the GC reaction regulation (Saito et 
al., 2007). The authors demonstrate 
that CD40 receptor engagement, usu-
ally caused in vivo by the interaction 
of GC lymphocytes with surrounding 
T cells at the terminal stages of GC 
reaction, leads to NF-κB-mediated 
transcriptional activation of the IRF4 
gene (Figure 1). Involvements of the 
p50 and p65 subunits, which bind 
the IRF4 promoter, suggest that the 
“canonical,” as opposed to the “alter-
native” NF-κB pathway mediates this 
process. Furthermore, the authors 07 Elsevier Inc.demonstrate that IRF4 transcrip-
tional factor binds to the promoter 
region of the BCL6 gene and directly 
represses its transcription (Figure 1). 
Taken with the current knowledge of 
specifically downregulated activity of 
the NF-κB pathway in normal GC B 
cells and upregulation of its activity 
upon maturation to post-GC stages, 
this finding is of paramount impor-
tance for the explanation of gene 
expression changes governing this 
differentiation process. Furthermore, 
since BCL6 was previously reported 
to negatively regulate expression of 
the NF-κB p105/p50 subunit (Li et 
al., 2005), this finding suggests an 
existence of a double-negative cir-
cuit regulating this differentiation 
step. This adds an additional dimen-
sion of complexity to the regulation 
of GC reaction in general and BCL6 
expression in particular. While previ-
ously attributed at least partially to 
the double-negative circuit involving 
BCL6 and Blimp-1 proteins, in which 
BCL6 binds to the Prdm1 gene and 
inhibits its transcription, whereas 
Blimp-1 protein represses the BCL6 
gene along with virtually every other 
GC signature gene (Shaffer et al., 
2002), the demonstration of NF-κB-
mediated regulation of BCL6 expres-
sion raises the possibility that multiple 
factors activating the canonical NF-
κB pathways may also be implicated 
in the regulation of BCL6 expres-
sion. Since IRF4-induced transcrip-
tional activity is usually determined 
by cofactors with which it interacts, 
future studies examining the nature 
of these cofactors in the GC microen-
vironment are necessary. Overall, the 
work presented here by Saito et al. is 
likely to open the way toward a better 
understanding of B cell differentiation 
and maturation.
These findings may also have 
important implications for our under-
standing of lymphoma pathogen-
esis. Saito et al. demonstrate that 
the major IRF4-binding domain in 
BCL6 gene overlap with the chro-
mosomal breakpoints and muta-
tions clusters in DLBCL and thus 
frequently is removed or altered by 
the translocations and mutations. 
The authors show that in DLBCL cell 
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binding domain in the BCL6 gene is 
removed or altered, activation of the 
CD40-NF-κB-IRF4 pathway fails to 
downregulate BCL6 gene expres-
sion. While previously translocations 
and mutations were implicated in 
deregulated expression of the BCL6 
gene by promoter substitution and 
elimination of the BCL6 autoregula-
tory loop, the findings reported by 
Saito et al. suggest that the resis-
tance to IRF4-mediated downregula-
tion may also represent an essential 
mechanism of BCL6 deregulation in 
tumors harboring translocated and 
mutated BCL6 alleles within the IRF-
4-responsive domain. The relative 
contribution of individual mecha-
nisms to deregulated expression of 
BCL6 will need to be evaluated in the 
future studies.
These new findings might also 
find their way to the clinic. DLBCL 
is the most prevalent subtype of 
lymphoma, accounting for 30%–
40% of non-Hodgkin’s lymphomas 
(NHL). At least two molecularly dis-tinct forms of the disease, defined 
by specific gene expression sig-
natures, are recognized: GC-like 
DLBCL, characterized by expres-
sion of genes normally expressed 
in GC B cells (including BCL6), and 
having a significantly better overall 
survival, and the activated B cell 
(ABC)-like DLBCL, characterized 
by high expression of NF-κB target 
genes (including IRF-4) (Alizadeh et 
al., 2000). Manipulating the BCL6-
NF-κB-IRF-4 proteins might be use-
ful in treating these lymphomas, 
given that inhibiting BCL6 in GC-
like DLBCL leads to cell death, while 
inhibition of NF-κB pathways leads 
to ABC-like DLBCL cell death. It is 
possible that the plasticity inherent 
in the BCL6-IRF-4 double-negative 
regulatory circuit may be exploited 
for therapeutic benefit.
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